Vircell
Private Company
Funding information not available
Overview
Vircell is an established, privately-held diagnostics company with nearly 30 years of experience in infectious disease testing. It has built a diversified product portfolio spanning traditional serology and modern molecular diagnostics, with a strong international commercial footprint. The company is currently emphasizing growth through its molecular quality control solutions (AMPLIRUN®) and laboratory automation (VirClia® Lotus), positioning itself as a comprehensive provider for diagnostic labs. Its sustained revenue generation is supported by a wide range of ready-to-use kits for bacterial, viral, fungal, and parasitic infections.
Technology Platform
Multi-methodology diagnostics platform encompassing serological assays (ELISA, IFA, CLIA via VirClia® Lotus) and molecular diagnostics (real-time PCR kits and independent molecular controls - AMPLIRUN®).
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Vircell competes in a fragmented but competitive global diagnostics market, facing off against large players like Abbott, Roche, and bioMérieux in serology and molecular diagnostics, as well as specialized control manufacturers. Its differentiation lies in its focused infectious disease expertise, broad pathogen menu, and combination of serology with molecular QA controls.